Ropeginterferon for cutaneous T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a medication called Ropeginterferon (a type of immune-supporting protein given as a shot) for people with different stages of cutaneous T-cell lymphoma. It may be an option if prior skin treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of cutaneous T-cell lymphoma (CTCL), including mycosis fungoides, Sézary syndrome, or other rare types.
- If your CTCL is early stage (IA-IB), you need to have tried at least two skin-directed treatments (like creams or light therapy) that didn't work or caused side effects.
- If your CTCL is more advanced (stage IIA-IIIB), you need to have tried phototherapy, ECP, or total skin electron beam therapy without a complete response.
- You must be 18 years or older and willing to receive a subcutaneous injection (a shot under the skin) every two weeks.
- You must not have large cell transformation on your skin biopsy, and you must have acceptable blood counts, liver, kidney, and thyroid function.
- Women who can become pregnant need a negative pregnancy test and must use effective contraception during and for 8 weeks after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at the results of different systemic (whole-body) treatments for cutaneous T-cell lymphoma (CTCL), a rare type of lymphoma that affects the skin. It aims to understand how well these therapies work and help guide future treatment choices.
This trial is testing new treatment plans based on the genetic type of your cutaneous T-cell lymphoma (CTCL). It's for people whose CTCL did not respond well to standard skin treatments.
This trial is testing a cream called tofacitinib (a type of medicine that helps calm the immune system) for people with early-stage cutaneous T-cell lymphoma (CTCL). The goal is to see if it helps shrink or control the skin lesions safely.
This Phase 2 trial studies two immune medicines (pembrolizumab and mogamulizumab) for people with advanced cutaneous T-cell lymphoma that has come back or did not respond to prior treatment. It aims to control the lymphoma and improve outcomes when the disease is hard to treat.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
This trial tests a tiny device placed directly into skin lymphoma spots to help identify which “candidate” drugs could work. It’s mainly aimed at people with measurable skin involvement from T-cell lymphoma, after they stop certain treatments for a set time.
Hear when a new Cutaneous T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.